New Study Confirms 98.9% Specificity Of The T-SPOT®.TB Assay
Oxford, UK [Marlborough, MA]; 26th April 2010 –
The authors of a recent peer-reviewed study published in the International Journal of Tuberculosis and Lung Disease confirmed the high specificity of the T-SPOT.TB assay.
Researchers from the Naval Institute for Dental and Biomedical Research, Great Lakes, Illinois, USA tested individuals who had recently graduated from the Recruit Training Command (Great Lakes, IL).
278 individuals categorized as being low risk for TB infection were tested, only 3 were positive for TB according to the T-SPOT.TB test. The resulting specificity of the T-SPOT.TB test is 98.9% (95%CI 96.9–99.8).
Commenting on the results, Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec said, “this study highlights the very high specificity of the T-SPOT.TB assay and confirms its utility in the identification of latent TB infection. The high specificity of the T-SPOT.TB assay virtually eliminates false positive results in subjects who are not infected, thereby avoiding unecessary follow up and treatment. This will dramatically improve the cost-effectiveness of TB control strategies”.
1. Bienek DR and Chang CK. Evaluation of an interferon-gamma release assay, T-SPOT®.TB, in a population with a low prevalence of tuberculosis. Int J Tuberc Lung Dis. 2009 Nov;13(11):1416-21.
이 사이트는 쿠키를 사용하여 귀하의 컴퓨터에 정보를 저장합니다. 본 사이트를 작동시키기 위해 필수 쿠키가 사용되며, 사용자 경험을 개선하기 위해서는 비-필수 쿠키가 사용됩니다. 쿠키 활성화 / 비활성화동의하기더 알아보기
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.